WuXi AppTec reported first-quarter 2026 total revenue of RMB 12.44 billion, an increase of 28.8% year over year, with revenue from continuing operations up 39.4%. Adjusted non-IFRS gross profit margin rose 8.5 percentage points to 50.4%. Adjusted non-IFRS net profit increased 71.7% to RMB 4.60 billion, with an adjusted non-IFRS net profit margin of 37.0% and adjusted non-IFRS diluted EPS of RMB 1.57. Net profit attributable to owners of the company was RMB 4.65 billion, up 26.7%, and diluted EPS was RMB 1.58. The backlog for continuing operations reached RMB 59.77 billion as of March 31, 2026, a 23.6% year-over-year increase, and adjusted operating cash flow grew 21.7% to RMB 3.69 billion.
Revenue growth was driven primarily by WuXi Chemistry, whose Q1 revenue rose 43.7% year over year to RMB 10.62 billion. The segment’s adjusted non-IFRS gross profit margin increased 5.4 percentage points to 52.8%. WuXi AppTec added 328 new molecules to its small molecule development and manufacturing (D&M) pipeline in the quarter. As of March 31, 2026, the small molecule D&M pipeline comprised 3,550 molecules, including 89 commercial projects, 94 in phase III, 386 in phase II, and 2,981 in phase I and preclinical stages; commercial and phase III projects increased by nine in the quarter. Small molecule D&M revenue reached RMB 6.93 billion, up 80.1% year over year. The TIDES (oligonucleotides and peptides) business reported Q1 revenue of RMB 2.38 billion, an increase of 6.1%, with full-year revenue expected to grow about 40%; TIDES D&M customers grew 28% and molecules 59% year over year.
WuXi Testing generated Q1 revenue of RMB 1.13 billion, up 27.4% year over year, including 34.8% growth in drug safety evaluation services. The segment’s adjusted non-IFRS gross profit margin increased 10.8 percentage points to 35.5%. New modality work, including nucleic acids, conjugates, multispecific antibodies and peptides, contributed more than 30% of WuXi Testing’s Q1 revenue. WuXi Biology recorded Q1 revenue of RMB 0.67 billion, a 10.1% year-over-year increase, and an adjusted non-IFRS gross profit margin of 36.7%, up 0.4 percentage points. New modality business also contributed more than 30% of WuXi Biology revenue, supported by expansion in nucleic acids, antibody conjugates and peptides.
The company stated it continues to pursue its “follow the molecule” and “win the molecule” strategies on its integrated CRDMO platform, and reaffirmed its full-year 2026 guidance, indicating it will consider raising guidance as market and business conditions warrant.